Search

CN-121975928-A - Be used for screening expansion kit for treating sex cardiomyopathy

CN121975928ACN 121975928 ACN121975928 ACN 121975928ACN-121975928-A

Abstract

The invention relates to a kit for screening dilated cardiomyopathy, which comprises reagents for detecting one or more of TP53, TNF, IL1 beta, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8 and NFKBIA genes. The kit provided by the invention has the advantages of high detection efficiency and low detection cost, provides an important reference basis for diagnosis and prognosis judgment of patients with dilated cardiomyopathy, and can obviously improve survival rate of patients.

Inventors

  • Xu Diezhou
  • WU YIRONG
  • GAO XIAOFEI
  • CHEN LIAN
  • PAN JIAHUI

Assignees

  • 杭州市第一人民医院

Dates

Publication Date
20260505
Application Date
20231205

Claims (10)

  1. 1. A kit for screening dilated cardiomyopathy, comprising reagents for detecting one or more of TP53, TNF, il1β, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8, and NFKBIA genes.
  2. 2. The kit of claim 1, wherein the kit comprises reagents for detecting one or more of TP53, TNF, il1β, JUN, CD8A, TLR4, UBB, and CXCL8 genes.
  3. 3. The kit of claim 2, wherein the kit comprises reagents for detecting one or more of TNF, il1β, TLR4 and UBB genes.
  4. 4. The kit of claim 3, wherein the kit comprises reagents for simultaneous detection of TNF, il1β, TLR4 and UBB genes.
  5. 5. The kit according to any one of claims 1 to 4, wherein the sample for detection by the kit is human venous blood.
  6. 6. Use of a kit for detecting one or more of TP53, TNF, il1β, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8, and NFKBIA genes in the preparation of a reagent for screening dilated cardiomyopathy.
  7. 7. The use according to claim 6, wherein the use is the use of a kit for detecting one or more of TP53, TNF, il1β, JUN, CD8A, TLR4, UBB and CXCL8 genes in the preparation of a reagent for screening dilated cardiomyopathy.
  8. 8. The use of claim 7, wherein the use is the use of a kit for detecting one or more of TNF, il1β, TLR4 and UBB genes in the preparation of a reagent for screening for dilated cardiomyopathy.
  9. 9. The use according to claim 8, wherein the use is the use of a kit for simultaneous detection of TNF, il1β, TLR4 and UBB genes in the preparation of a reagent for screening for dilated cardiomyopathy.
  10. 10. The use according to any one of claims 6 to 9, wherein the sample for detection by the kit is human venous blood.

Description

Be used for screening expansion kit for treating sex cardiomyopathy Technical Field The invention relates to the field of biological detection, in particular to a kit for screening dilated cardiomyopathy. Background Dilated Cardiomyopathy (DCM) is a myocardial disease of unknown etiology, meaning that left ventricle dilatation and/or contractile dysfunction is present in the absence of abnormal loading conditions and severe coronary artery disease. Epidemiological studies have shown a global prevalence of about 1/2500-1/150, mainly young and young, with men more than women (3:1). According to current guidelines, DCM clinical diagnosis is based primarily on clinical symptoms and signs of the patient, as well as electrocardiogram, echocardiogram and cardiac magnetic resonance. DCM is an exclusive diagnosis, excluding hypertension, ischemic cardiomyopathy, valvular heart disease, etc., and lacks specific diagnostic methods to rapidly identify DCM early. With the wide application of high throughput sequencing technology in clinical practice, the knowledge of DCM at the gene level is greatly accelerated. More than 60 genes encoding myoglobin, cytoskeletal proteins and myomembrane proteins have been identified to date as being associated with DCM. Although numerous studies confirm that numerous molecular markers are closely related to the development of DCM, none of them has been applied to conventional clinical assays so far, and most studies have not conducted clinical relevance analysis and genetically linked prognostic analysis, much more experimentation is needed for the study of early diagnosis and prognostic analysis of DCM. At present, no related report of a kit capable of efficiently screening dilated cardiomyopathy is found. Disclosure of Invention In order to solve the technical problems, the invention comprises the following aspects: in a first aspect, the invention provides a kit for screening for dilated cardiomyopathy comprising reagents for detecting one or more of the TP53, TNF, IL 1. Beta., JUN, CD8A, TLR, UBB, CTLA4, CXCL8, and NFKBIA genes. Preferably, the kit includes reagents for detecting one or more of the TP53, TNF, IL 1. Beta., JUN, CD8A, TLR4, UBB, and CXCL8 genes. More preferably, the kit includes reagents for detecting one or more of TNF, il1β, TLR4 and UBB genes. Further preferred, the kit comprises reagents for simultaneous detection of TNF, il1β, TLR4 and UBB genes. Preferably, the reagent for detecting TP53 gene comprises a primer pair shown as SEQ ID NO.1 and SEQ ID NO.2, the reagent for detecting TNF gene comprises a primer pair shown as SEQ ID NO.3 and SEQ ID NO.4, the reagent for detecting IL1 beta gene comprises a primer pair shown as SEQ ID NO.5 and SEQ ID NO.6, the reagent for detecting JUN gene comprises a primer pair shown as SEQ ID NO.7 and SEQ ID NO.8, the reagent for detecting CD8A gene comprises a primer pair shown as SEQ ID NO.9 and SEQ ID NO.10, the reagent for detecting TLR4 gene comprises a primer pair shown as SEQ ID NO.11 and SEQ ID NO.12, the reagent for detecting UBB gene comprises a primer pair shown as SEQ ID NO.13 and SEQ ID NO.14, the reagent for detecting CTLA4 gene comprises a primer pair shown as SEQ ID NO.15 and SEQ ID NO.16, the reagent for detecting CX8 gene comprises a primer pair shown as SEQ ID NO.17 and SEQ ID NO.18, and the reagent for detecting NFA gene shown as SEQ ID NO. 20. Preferably, the kit further comprises Ficoll separation liquid, an RNA extraction reagent, a reverse transcription reagent and a PCR system reagent. Preferably, the RNA extraction reagent comprises RNA lysate, washbuffer, and Solutionbuffer. More preferably, the RNA extraction reagent is an RNA rapid extraction kit (RNA-Quick Purification Kit) purchased from Shanghai Yi fir Biotech Co. Preferably, the reverse transcription reagent comprises EasyQuick RT MasterMix and enzyme-free water, and the EasyQuick RT MasterMix contains Oligo (dT), randomprimer, RNase Inhibitor, dNTP mix and EQ-RT Buffer. Preferably, the PCR system reagents include UltraSYBR Mixture and enzyme-free water. Preferably, the sample for detection of the kit is human venous blood. In a second aspect, the invention provides the use of a kit for detecting one or more of the TP53, TNF, IL1 beta, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8 and NFKBIA genes in the preparation of a reagent for screening dilated cardiomyopathy. Preferably, the invention provides the use of a kit for detecting one or more of the TP53, TNF, IL1 beta, JUN, CD8A, TLR4, UBB and CXCL8 genes in the preparation of a reagent for screening dilated cardiomyopathy. More preferably, the invention provides the use of a kit for detecting one or more of TNF, il1β, TLR4 and UBB genes in the preparation of a reagent for screening dilated cardiomyopathy. Further preferred, the invention provides the use of a kit for simultaneous detection of TNF, il1β, TLR4 and UBB genes in the preparation of a reagent for screening dilated cardiomyopathy. Preferably, the r